State of organic seeds in France

A comprehensive range of investigations carried out between 2010 and 2012 provided information on the state of organic seeds in France. Results fit with the hypothesis that the market is a significant factor influencing the choice of seeds and cultivars (local cultivars, landraces, modern cultivars). Expectations and practices of producers selling on a local market (i.e., direct sale) differ radically from those of producers selling to long food supply chains. This study showed that the availability and use of organic seeds have significantly improved over the last three years. A vast majority of organic producers willingly use organic seeds, with, on average, 45-70 % (cereals), and 75%-100 % (vegetables) of organic seeds being planted on farms. However, the total number of derogations remained quite high: there is still space for improvement in organic seed use and supply in France. Several limiting factors and levers were identified during the study, as well as farmers’ expectations for the future on cereals, forage crops and vegetables. This study described an action plan, which must be carefully implemented. The organic sector depends on the development of a wide and adapted range of organic seeds

The management of acute venous thromboembolism in clinical practice. Results from the European PREFER in VTE Registry

Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in Europe. Data from real-world registries are necessary, as clinical trials do not represent the full spectrum of VTE patients seen in clinical practice. We aimed to document the epidemiology, management and outcomes of VTE using data from a large, observational database. PREFER in VTE was an international, non-interventional disease registry conducted between January 2013 and July 2015 in primary and secondary care across seven European countries. Consecutive patients with acute VTE were documented and followed up over 12 months. PREFER in VTE included 3,455 patients with a mean age of 60.8 ± 17.0 years. Overall, 53.0 % were male. The majority of patients were assessed in the hospital setting as inpatients or outpatients (78.5 %). The diagnosis was deep-vein thrombosis (DVT) in 59.5 % and pulmonary embolism (PE) in 40.5 %. The most common comorbidities were the various types of cardiovascular disease (excluding hypertension; 45.5 %), hypertension (42.3 %) and dyslipidaemia (21.1 %). Following the index VTE, a large proportion of patients received initial therapy with heparin (73.2 %), almost half received a vitamin K antagonist (48.7 %) and nearly a quarter received a DOAC (24.5 %). Almost a quarter of all presentations were for recurrent VTE, with >80 % of previous episodes having occurred more than 12 months prior to baseline. In conclusion, PREFER in VTE has provided contemporary insights into VTE patients and their real-world management, including their baseline characteristics, risk factors, disease history, symptoms and signs, initial therapy and outcomes

Organic seeds and plant breeding: Stakeholders' uses and expectations - French inputs on vegetables

All organic agricultural systems suffer from a lack of plant cultivars adapted to organic production. Within the framework of the European project SOLIBAM (Strategies for Organic and Low Input Breeding and Management) a study was undertaken to determine which cultivars farmers grow, why they grow them, and the expectations in plant breeding of organic stakeholders. A comprehensive range of investigations carried out between 2010 and 2012 provided information on the state of organic seed in France. Results fit with the hypothesis that the market is a significant factor influencing the choice of seeds and cultivars (local cultivars, landraces, modern cultivars). Expectations and practices of producers selling on a local market (i.e., direct sale) differ radically from those of producers selling to long food supply chains. This study shows that the availability and use of organic seeds have significantly improved over the last three years. A vast majority of organic producers willingly use organic seeds, with, on average, 45-70% (cereals) and 75%-100% (vegetables) of organic seeds being planted on farms. However, the total number of derogations remains quite high: there is still space for improvement in organic seed use and supply in France. Several limiting factors and levers were identified during the study, as well as farmers' expectations for the future on horticultural crops. The case study on tomatoes states the differences between producers selling on a local market and those of producers selling in long food supply chains regarding their practices (open field vs greenhouses) and the kind of cultivar they use or wish to have

De nouvelles pommes pour demain ! 1ers résultats d'une expérimentation nationale en réseau

National audienc

De nouvelles pommes pour demain ! Premiers résultats d'une expérimentation nationale en réseau

National audienc

The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

Background: Venous thromboembolism (VTE) is a major health problem, with over one million events every year in Europe. However, there is a paucity of data on the current management in real life, including factors influencing treatment pathways, patient satisfaction, quality of life (QoL), and utilization of health care resources and the corresponding costs. The PREFER in VTE registry has been designed to address this and to understand medical care and needs as well as potential gaps for improvement. Methods/design: The PREFER in VTE registry was a prospective, observational, multicenter study conducted in seven European countries including Austria, France Germany, Italy, Spain, Switzerland, and the UK to assess the characteristics and the management of patients with VTE, the use of health care resources, and to provide data to estimate the costs for 12 months treatment following a first-time and/or recurrent VTE diagnosed in hospitals or specialized or primary care centers. In addition, existing anticoagulant treatment patterns, patient pathways, clinical outcomes, treatment satisfaction, and health related QoL were documented. The centers were chosen to reflect the care environment in which patients with VTE are managed in each of the participating countries. Patients were eligible to be enrolled into the registry if they were at least 18 years old, had a symptomatic, objectively confirmed first time or recurrent acute VTE defined as either distal or proximal deep vein thrombosis, pulmonary embolism or both. After the baseline visit at the time of the acute VTE event, further follow-up documentations occurred at 1, 3, 6 and 12 months. Follow-up data was collected by either routinely scheduled visits or by telephone calls. Results: Overall, 381 centers participated, which enrolled 3,545 patients during an observational period of 1 year. Conclusion: The PREFER in VTE registry will provide valuable insights into the characteristics of patients with VTE and their acute and mid-term management, as well as into drug utilization and the use of health care resources in acute first-time and/or recurrent VTE across Europe in clinical practice. Trial registration: Registered in DRKS register, ID number: DRKS0000479